Skip to main content

Exact Sciences Value Stock - Dividend - Research Selection

Exact sciences

ISIN: US30063P1057 , WKN: 590273

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


'Abbott Laboratories Kicks Off Bond Sale for Exact Sciences Deal' - Bloomberg

2026-02-23
https://www.bloomberg.com/news/articles/2026-02-23/abbott-laboratories-kicks-off-bond-sale-for-exact-sciences-deal

Exact Sciences Stockholders Voted To Approve Proposed Acquisition By Abbott

2026-02-20
At the special meeting, preliminary results showed that more than 99% of the votes cast, representing approximately 67% of the total outstanding shares of Exact Sciences common stock as of the January 9, 2026 record date

Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells

2026-02-15

Exact Sciences Earnings Review: Q4 Summary

2026-02-13

Exact Sciences Q4 Adj. EPS $(0.21) Misses $(0.07) Estimate, Sales $878.381M Beat $860.895M Estimate

2026-02-13
Exact Sciences (NASDAQ:EXAS) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.07) by 218.18 percent. This is a 250 percent decrease over losses of $(0.06) per share from

Alger Mid Cap 40 ETF Q4 2025 Portfolio Update

2026-02-12

Baron Opportunity Fund Q4 2025 Portfolio Activity

2026-02-12
We invest in secular growth and innovative businesses across all market capitalizations, with the bulk of the portfolio landing in the large-cap zone. Read more here.

Soft Start For $10B-Plus M&A Deals In 2026

2026-02-10

Hims & Hers Is Offering a New Cancer Test. It May Not Be Ready for Prime Time.

2026-02-09
A new Super Bowl ad from Hims & Hers is giving some medical experts pause. In addition to touting the company’s weight loss drugs and testosterone treatments, it promotes a controversial early cancer detection test. Hims & Hers charges $689 for the test, which involves a blood draw and a prescription by a medical professional.

1 Momentum Stock with Exciting Potential and 2 Facing Headwinds

2026-02-09
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.